I agree that this site is using cookies. You can find further informations here.
X
Rordorf, Tamara
44  results:
Search for persons X
?
1

Long-term Outcomes with Nivolumab as First-line Treatment i..:

Gillison, Maura L ; Blumenschein Jr, George ; Fayette, Jerome...
The Oncologist.  27 (2022)  2 - p. e194-e198 , 2022
Link: https://doi.org/10.1093/..
 
?
2

Pembrolizumab alone or with chemotherapy for recurrent or m..:

Rischin, Danny ; Harrington, Kevin J. ; Greil, Richard...
Oral Oncology.  128 (2022)  - p. 105815 , 2022
Link: https://doi.org/10.1016/..
 
?
3

SalvGlandDx – a comprehensive salivary gland neoplasm speci..:

Freiberger, Sandra N. ; Brada, Muriel ; Fritz, Christine...
Neoplasia.  23 (2021)  5 - p. 473-487 , 2021
Link: https://doi.org/10.1016/..
 
?
4

IL-36γ drives skin toxicity induced by EGFR/MEK inhibition ..:

Satoh, Takashi K. ; Mellett, Mark ; Meier-Schiesser, Barbara...
Journal of Clinical Investigation.  130 (2020)  3 - p. 1417-1430 , 2020
Link: https://doi.org/10.1172/..
 
?
5

Consolidation cetuximab after concurrent triplet radiochemo..:

Riesterer, Oliver ; Pruschy, Martin ; Bender, Sabine...
Radiotherapy and Oncology.  150 (2020)  - p. 62-69 , 2020
Link: https://doi.org/10.1016/..
 
?
6

Pembrolizumab alone or with chemotherapy versus cetuximab w..:

Burtness, Barbara ; Harrington, Kevin J ; Greil, Richard...
The Lancet.  394 (2019)  10212 - p. 1915-1928 , 2019
Link: https://doi.org/10.1016/..
 
?
7

Sequential somatic mutations upon secondary anti-HER2 treat..:

Nordmann, Thierry M. ; Messerli-Odermatt, Olivia ; Meier, Larissa...
Oncotarget.  10 (2019)  62 - p. 6647-6650 , 2019
Link: https://doi.org/10.18632..
 
?
8

Nivolumab vs investigator's choice in recurrent or metastat..:

Ferris, Robert L. ; Blumenschein Jr., George ; Fayette, Jerome...
Oral Oncology.  81 (2018)  - p. 45-51 , 2018
Link: https://doi.org/10.1016/..
 
?
9

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivol..:

Gillison, Maura L. ; Blumenschein Jr., George ; Fayette, Jerome...
The Oncologist.  23 (2018)  9 - p. 1079-1082 , 2018
Link: https://doi.org/10.1634/..
 
?
10

18FDG-PET-CT identifies histopathological non-responders af..:

Schneider, Paul M. ; Eshmuminov, Dilmurodjon ; Rordorf, Tamara...
BMC Cancer.  18 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
?
11

Denosumab as a Treatment Alternative for Central Giant Cell..:

Bredell, Marius ; Rordorf, Tamara ; Kroiss, Sabine...
Journal of Oral and Maxillofacial Surgery.  76 (2018)  4 - p. 775-784 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen..:

Rostetter, Claudio ; Rordorf, Tamara ; Essig, Harald...
SWISS DENTAL JOURNAL SSO – Science and Clinical Topics.  127 (2017)  6 - p. 520-521 , 2017
Link: https://doi.org/10.61872..
 
?
13

SAKK 24/09: safety and tolerability of bevacizumab plus pac..:

on behalf of the Swiss Group for Clinical Cancer Research (SAKK) ; Rochlitz, Christoph ; Bigler, Martin...
BMC Cancer.  16 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
14

IMRT/VMAT for malignancies in the head-and-neck region: Out..:

Brown, Michelle L. ; Glanzmann, Christoph ; Huber, Gerhard...
Strahlentherapie und Onkologie.  192 (2016)  8 - p. 526-536 , 2016
Link: https://doi.org/10.1007/..
 
?
15

Expression of CK19 is an independent predictor of negative ..:

Ernst, Jutta ; Ikenberg, Kristian ; Apel, Barbara...
Oncotarget.  7 (2016)  46 - p. 76151-76158 , 2016
Link: https://doi.org/10.18632..
 
1-15